Articles On Kazia Therapeutics (ASX:KZA)

SYDNEY, July 6, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pedi...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) has made good progress in the first six months of the year with pipeline assets paxalisib and EVT801 despite a challenging equity market for biotech companies. A Phase I study of...

Kazia Therapeutics (ASX:KZA) has announced that the US FDA has granted Orphan Drug Designation to its paxalisib for the treatment of atypical rhabdoid/teratoid tumours.

SYDNEY, June 17, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan D...

The US FDA has awarded Kazia Therapeutics (KZA) Orphan Drug Designation (ODD) for its paxalisib drug to treat a rare type of childhood brain cancer The designation is for paxalisib to treat atypical rhabdoid/teratoid tumours which is a rar...

Highlights Kazia Therapeutics’ lead drug candidate, Paxalisib, secures ODD from the FDA for the treatment of a kind of brain cancer. Kazia will save over US$3 million in fees related to a future regulatory filing in atypical rhabdoid/t...

Kazia gets designation approval from US FDA Lumos signs contract to make at-home screening test product Trajan acquires US-based company, in trading halt Oncology company Kazia Therapeutics (ASX:KZA) says its lead drug paxalisib has been...

Kazia Therapeutics (ASX: KZA) has collared orphan drug designation (ODD) from the United States Food and Drug Administration for its lead candidate paxalisib in treating a rare and highly aggressive childhood brain cancer. The ODD is specif...

ShareCafeEvening Report: 14 June, 2022 by Paul Sanger   The Australian sharemarket has suffered its worst losses in over two years, obliterating $82bn of market capitalisation off the ASX 200. At the closing bell, the S&P/ASX 200 plunge...

“Positive data” is being presented regarding the activity of Kazia Therapeutics’ (ASX: KZA) lead drug paxalisib in two forms of childhood brain cancers. The company is presenting the data via two presentations this week at the 20th Internat...

14 Jun 2022 - A snapshot of the stocks on the move featuring Kazia Therapeutics (ASX:KZA), Westgold Resources (ASX:WGX) & Lake Resources (ASX:LKE).

Kazia Therapeutics (KZA) sees new data presented for its brain cancer drug, Paxalisib, highlighting its use in two forms of childhood brain cancer The data has been presented in two poster presentations at the International Symposium on Pe...

SYDNEY, June 13, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the presentation of new data regarding the activity of paxalisib in two forms...

Oncology-focused drug developer Kazia Therapeutics (ASX: KZA) is expanding a phase two study of its drug paxalisib in patients with brain metastases to include those starting from breast cancer. The genomically-guided study, led by the US-b...

SYDNEY, June 7, 2022 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II, genomically-guided study of multiple therapies in patients with brain metasta...

ShareCafeQueuing at the ATM: ASX small caps discover a handy source of funding ASX-listed small cap companies are flocking to the ATM for a ready source of cash, at a time and amount of their choosing. In this case, ATM does not refer to th...

SYDNEY, June 3, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce final data from its phase II study of paxalisib as first line therapy in patien...

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has confirmed the multi-drug platform study GBM AGILE has opened recruitment to its paxalisib arm in Europe. GBM AGILE is a global, academic-led study designed to ident...

SYDNEY, May 31, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the GBM AGILE study in glioblastoma (NCT03970447) has opened recruitment t...

SYDNEY, May 23, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at two upcoming investor conferen...

SYDNEY, May 17, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks ‘DIPG Awareness Day’ by recognizing the tireless work of global researchers in this d...

11 May 2022 - A snapshot of stocks in the healthcare sector, including Antisense Therapeutics (ASX:ANP), Kazia Therapeutics (ASX:KZA), and Immutep (ASX:IMM).

The deep sell down of the US biotech sector has resulted in the valuation of many of the ASX-listed life science plays looking a tad sickly, too. Arguably, many of them were overvalued in the first place. But in many cases the companies ar...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Oncology-focused drug development company Kazia Therapeutics (KZA) establishes an “at-the-market” equity program, with Oppenheimer & Co acting as sales agent Under the ATM, Kazia may offer and sell via Oppenheimer up to US$35 million (...

Oncology-focused biotechnology company Kazia Therapeutics (ASX: KZA) has established an ‘at-the-market’ (ATM) equity program, appointing US-based investment bank Oppenheimer & Co Inc as the sales agent. Under the program, the drug devel...

Kazia Therapeutics (ASX:KZA) has established an ‘at-the-market’ equity program with Oppenheimer & Co.

Kazia Therapeutics (ASX: KZA) is preparing to present the results of a phase II study evaluating its lead drug paxalisib in glioblastoma, which is the most aggressive form of brain cancer. The phase II study is now complete, and Kazia has t...

Oncology-focused drug development company Kazia Therapeutics (ASX:KZA) has announced that its phase 2 study of paxalisib in glioblastoma (NCT03522298) has been successfully completed.

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

SYDNEY, April 8, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce new preclinical data demonstrating the activity of paxalisib in two forms of c...

SYDNEY, April 8, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce two presentations detailing the ongoing phase I study of the compan...

Pro Medicus signs $32m deal in the US Kazia shows promise with lead drug paxalisib in child cancer Pro Medicus signs $32m deal Health imaging company ProMedicus (ASX:PME) has struck a significant deal with Inova Health System, the leading...

Kazia Therapeutics (ASX: KZA) has revealed pre-clinical data that its drug paxalisib demonstrates activity in two forms of childhood brain cancer where there is a very high unmet medical need. The company presented the pre-clinical data at...

ShareCafeWebinar Recap – SLB, MX1, KZA & AKO Catch up on the full webinar with presentations from Stelar Metals (ASX: SLB), My Foodie Box (ASX: MBX), Kazia Therapeutics (ASX: KZA) & Akora Resources (ASX: AKO) Webinar Recap – SLB, M...

ShareCafeKazia Therapeutics (ASX: KZA) – Webinar presentation James Garner – CEO & MD – Kazia Therapeutics Limited is an innovative oncology-focused biotechnology company. Kazia is working to develop therapies across a range of oncolog...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

ShareCafeKey Points To Remember When Investing in Biotech Companies In my role as Research Analyst for Corporate Connect, I have just released a report giving an in-depth assessment of the present state of the global biotech sector and, in...

SYDNEY, March 21, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late stage, oncology-focused drug development company, is pleased to announce upcoming presentations at two international conferences. America...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

SYDNEY, Feb. 28, 2022 /PRNewswire/ – Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in combi...

This important milestone kicks off an exciting year for Kazia, with at least six potential data read-outs anticipated over the course of 2022.

Oncology-focused drug development company Kazia Therapeutics (ASX: KZA) has recruited its first patient into a Phase II study of investigational new drug paxalisib for the treatment of newly-diagnosed and recurrent glioblastoma. The two-yea...

GBM AGILE, the pivotal study of paxalisib in glioblastoma, is well-advanced, having commenced recruitment to the paxalisib arm in January 2021.

Kazia Therapeutics says it had $15.2 million in cash at the end of December 2021 having committed $11.4 million during the period to progress its pipeline.

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Oncology-focused and clinical stage biotechnology company Kazia Therapeutics (ASX: KZA) has reported strong progress on the development of its lead drug candidates during the three months to 31 December. Work focused on studies for brain ca...

SYDNEY, Feb. 7, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the BIO CEO Conference, to be...

SYDNEY, Jan. 25, 2022 /PRNewswire/ — Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be speaking at the Edison Group ‘Open House’ E...